Bioenterics Corporation
Bioenterics Corporation, headquartered in the United States, is a pioneering entity in the medical device industry, specialising in innovative solutions for obesity and metabolic disorders. Founded in the early 2000s, the company has made significant strides in developing minimally invasive technologies that enhance patient outcomes. With a focus on products such as the Bioenterics Intragastric Balloon, Bioenterics stands out for its commitment to safety and efficacy, offering unique solutions that cater to the growing demand for non-surgical weight loss options. The company has established a strong market position, recognised for its contributions to the field of bariatric medicine. Bioenterics Corporation continues to lead the way in advancing therapeutic options, making a notable impact on the lives of patients seeking effective weight management solutions.
DitchCarbon Score
How does Bioenterics Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioenterics Corporation's score of 36 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioenterics Corporation, headquartered in the US, currently does not report specific carbon emissions data, as there are no available figures for emissions in kg CO2e. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and initiatives. While Bioenterics does not have its own reduction targets, it inherits sustainability initiatives from AbbVie Inc. at a cascade level of three. AbbVie has set various climate commitments, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which guide its subsidiaries in reducing their carbon footprints. As part of its corporate family, Bioenterics aligns with AbbVie’s broader climate strategies, although specific targets or achievements for Bioenterics are not detailed. The company is expected to adhere to the sustainability practices and reduction goals established by its parent organisation, contributing to a collective effort towards climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioenterics Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
